Acadian Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.18M | Buy |
111,516
+93,385
| +515% | +$4.49M | 0.01% | 794 |
|
|
2026
Q1 | $934K | Sell |
18,131
-288,534
| -94% | -$14.7M | ﹤0.01% | 1185 |
|
|
2025
Q4 | $15.2M | Buy |
306,665
+82,522
| +37% | +$4.01M | 0.03% | 384 |
|
|
2025
Q3 | $10.7M | Buy |
224,143
+214,969
| +2,343% | +$8.66M | 0.02% | 465 |
|
|
2025
Q2 | $289K | Hold |
9,174
| – | – | ﹤0.01% | 1245 |
|
|
2025
Q1 | $300K | Buy |
9,174
+6,934
| +310% | +$246K | ﹤0.01% | 1180 |
|
|
2024
Q4 | $80K | Buy |
2,240
+877
| +64% | +$30.9K | ﹤0.01% | 1394 |
|
|
2024
Q3 | $42K | Buy |
+1,363
| New | +$42.5K | ﹤0.01% | 1848 |
|
|
2021
Q2 | – | Sell |
-13,258
| Closed | -$347K | – | 2200 |
|
|
2021
Q1 | $347K | Sell |
13,258
-165,331
| -93% | -$4.62M | ﹤0.01% | 1319 |
|
|
2020
Q4 | $4.49M | Sell |
178,589
-238,872
| -57% | -$5.14M | 0.02% | 526 |
|
|
2020
Q3 | $8.7M | Sell |
417,461
-253,454
| -38% | -$5.75M | 0.04% | 337 |
|
|
2020
Q2 | $15.9M | Buy |
670,915
+250,467
| +60% | +$5.53M | 0.07% | 249 |
|
|
2020
Q1 | $7.57M | Buy |
420,448
+1,519
| +0.4% | +$31.9K | 0.04% | 309 |
|
|
2019
Q4 | $9.94M | Sell |
418,929
-108,646
| -21% | -$2.64M | 0.05% | 304 |
|
|
2019
Q3 | $14.5M | Sell |
527,575
-60,826
| -10% | -$1.8M | 0.06% | 265 |
|
|
2019
Q2 | $19.5M | Sell |
588,401
-145,997
| -20% | -$5M | 0.09% | 192 |
|
|
2019
Q1 | $25.7M | Buy |
734,398
+9,364
| +1% | +$348K | 0.11% | 176 |
|
|
2018
Q4 | $24.1M | Sell |
725,034
-147,856
| -17% | -$6.36M | 0.12% | 165 |
|
|
2018
Q3 | $44M | Sell |
872,890
-249,115
| -22% | -$12.3M | 0.18% | 126 |
|
|
2018
Q2 | $67.2M | Sell |
1,122,005
-18,414
| -2% | -$954K | 0.29% | 91 |
|
|
2018
Q1 | $52.2M | Sell |
1,140,419
-139,760
| -11% | -$5.83M | 0.23% | 101 |
|
|
2017
Q4 | $51M | Buy |
1,280,179
+24,491
| +2% | +$968K | 0.22% | 107 |
|
|
2017
Q3 | $50.2M | Sell |
1,255,688
-301,856
| -19% | -$13.1M | 0.22% | 109 |
|
|
2017
Q2 | $67.1M | Sell |
1,557,544
-63,254
| -4% | -$2.25M | 0.3% | 89 |
|
|
2017
Q1 | $50.7M | Sell |
1,620,798
-41,301
| -2% | -$1.11M | 0.23% | 106 |
|
|
2016
Q4 | $42M | Sell |
1,662,099
-75,427
| -4% | -$1.69M | 0.2% | 114 |
|
|
2016
Q3 | $43M | Buy |
1,737,526
+210,249
| +14% | +$4.76M | 0.21% | 123 |
|
|
2016
Q2 | $31.1M | Buy |
1,527,277
+67,870
| +5% | +$1.2M | 0.16% | 142 |
|
|
2016
Q1 | $22.3M | Sell |
1,459,407
-173,276
| -11% | -$2.26M | 0.11% | 188 |
|
|
2015
Q4 | $21.9M | Buy |
1,632,683
+913,129
| +127% | +$14.1M | 0.11% | 192 |
|
|
2015
Q3 | $10.1M | Buy |
719,554
+116,534
| +19% | +$2.17M | 0.06% | 287 |
|
|
2015
Q2 | $10.2M | Buy |
+603,020
| New | +$8.58M | 0.05% | 286 |
|
Other funds holding SUPN
VPM
VCM
SIMG
GKIM
Acadian Asset Management's SUPN Position: Q2 2026 in Review
Acadian Asset Management increased its Supernus Pharmaceuticals (SUPN) stake by 515% in Q2 2026, buying an estimated $4.49M and bringing the position to 111,516 shares worth $5.18M. The position accounts for 0.01% of the portfolio, ranked #794.
Acadian Asset Management first reported a position in SUPN in Q2 2015 and has held it in 32 quarters since. The position peaked at $67.2M in Q2 2018. 242 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Acadian Asset Management held 111,516 shares of Supernus Pharmaceuticals worth $5.18M as of Q2 2026.
- Acadian Asset Management bought 93,385 Supernus Pharmaceuticals shares in Q2 2026, an estimated $4.49M.
- Supernus Pharmaceuticals made up 0.01% of Acadian Asset Management's portfolio in Q2 2026, its #794 holding.
- Acadian Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 32 quarters since.
- Acadian Asset Management's Supernus Pharmaceuticals position peaked at $67.2M in Q2 2018.
- 242 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.